Navigation Links
Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
Date:6/3/2008

Results presented at American Society of Clinical Oncology meeting indicate

CPX-1 improved clinical outcomes compared to historical data.

PRINCETON, N.J., June 3 /PRNewswire/ -- Celator Pharmaceuticals reported positive results from its CPX-1 Phase 2 clinical trial in patients with advanced colorectal cancer. CPX-1 is a liposomal formulation of irinotecan and floxuridine, based on the company's proprietary CombiPlex(TM) technology. The results were presented in a poster presentation at the American Society of Clinical Oncology meeting in Chicago.

The CombiPlex(TM) drug ratio technology platform is a new approach which identifies a ratio of drugs that will deliver a synergistic benefit, locks the desired ratio in a drug delivery vehicle and maintains the ratio in patients with the goal of improving clinical outcomes.

The multi-center, open-label, Phase 2 study had two arms, irinotecan-nave (IRI-naive) and irinotecan-refractory (IRI-refractory). IRI-naive patients had less than or equal to 2 prior regimens; one adjuvant/neoadjuvant and no more than 1 regimen for advanced disease. IRI-refractory patients had disease progression within 6 months of prior irinotecan-containing treatment and started CPX-1 treatment within 12 months of disease progression following irinotecan. Patients received 210 units/m2 of CPX-1 every two weeks.

Twenty-six patients were treated in the IRI-naive arm. The overall response rate (ORR) was 8 percent and the disease control rate (patients who achieved a response or stable disease) was 65 percent. Median progression- free survival (PFS) was 3.9 months. Six patients had a >6 month PFS. These data compare favorably to results published from other studies with irinotecan or an irinotecan-based regimen in this patient population which report an approximate 4 percent response rate and median PFS of 2.5 months.

Thirty-three patients were treated in the IRI-refractory arm. The disease control rate was 45 percent; no patient achieved an objective response. The median PFS was 2.3 months. Three patients had a >6 month PFS. The disease control and median PFS are similar to results achieved in this patient population for approved agents (panitumumab or cetuximab monotherapy).

Safety data were qualitatively similar to that of irinotecan and a fluoropyrimidine with neutropenia, diarrhea, nausea, vomiting and fluid loss events (dehydration and hypokalemia) being the most common. The 210 unit/m2 dose produced more toxicities than seen in the CPX-1 Phase 1 clinical trial, resulting in only 40 percent of patients receiving >80 percent of the planned dose intensity. Treatment will be initiated at a lower dose in future studies.

"The efficacy results in this study are very encouraging, particularly compared to historical data," said Arthur Louie, M.D., chief medical officer of Celator. "These data support that drug ratios may play an important role when combining drugs to treat patients. This study shows that well established drugs with proven activity may offer greater clinical benefit when a synergistic ratio is identified and the individual drugs are locked into a drug delivery vehicle able to deliver and maintain the desired ratio in patients. Our goal is to substantially improve clinical outcomes by using our proprietary CombiPlex(TM) technology."

About Celator

Celator Pharmaceuticals, Inc., is a privately held pharmaceutical company working to develop new and more effective therapies to treat cancer. CombiPlex(TM), the company's drug ratio technology platform, represents a revolutionary new approach that identifies a ratio of drugs that will deliver a synergistic benefit, locks the desired ratio in a drug delivery vehicle and maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes: CPX-1 (a liposomal formulation of irinotecan:floxuridine), currently in a Phase 2 trial in patients with colorectal cancer; CPX-351 (a liposomal formulation of cytarabine:daunorubicin), currently in a Phase 1 trial in patients with leukemia; CPX 571 (a liposomal formulation of irinotecan:cisplatin), a preclinical stage compound; and multiple research programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents. For more information, please visit the company's website at http://www.celatorpharma.com.


'/>"/>
SOURCE Celator Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
2. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
3. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
4. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
5. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
6. Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
9. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
10. Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting
11. Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... March 28, 2017  Medeon Biodesign, Inc., a ... is pleased to announce that the Company led ... Panther Orthopedics, Inc., a San Jose, ... solutions for orthopedic extremity applications.  ... rapidly, primarily due to procedure volume growth, lifestyle ...
(Date:3/28/2017)... , Va. and PHOENIX , March 28, ... Avella Specialty Pharmacy released a new white ... allergies and the use of latex in healthcare. Specifically, there ... in healthcare. In fact, the FDA has urged manufacturers to ... latex" claim from labels, because of the challenge to ensure ...
(Date:3/28/2017)... Kingdom and  BOSTON , March 28, 2017 ... Linguamatics today announced a partnership with premium ... agreement allows pharmaceutical companies to extract key insights ... text mining technology. The Linguamatics ... the top 20 global pharmaceutical companies. The Linguamatics-Dow ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... ... advancing the science and clinical practice of radiosurgery, announced today the publication ... multi-institutional, observational registry established to standardize data collection from patients treated with ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... today that the University of Pittsburgh Medical Center (UPMC) will acquire QuikClot® Bleeding ... Pennsylvania. , The program, developed in association with efforts by the American College ...
(Date:3/28/2017)... ... , ... The Radiology Business Management Association (RBMA) is pleased to ... executive director. Mr. Still was selected through a careful months-long search by the RBMA ... known to our members, has been a part of building the RBMA since 1992,” ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... Wethersfield, Conn., has relocated its corporate headquarters to a new, more expansive office ... , In October 2016, Qualidigm purchased a distressed office building in Wethersfield, Conn. ...
(Date:3/28/2017)... ... March 28, 2017 , ... METTLER ... ions found in power plant water and steam. , Chlorides and sulfates cause ... boilers, leading to extensive maintenance and unplanned shutdowns. Monitoring these ions at low ...
Breaking Medicine News(10 mins):